(Q42654373)

English

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

based on heuristic

inferred from title

Jon A Kobashigawa

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

David K

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Morris J

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Chu AH

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Steffen BJ

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Gotz VP

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Gordon RD

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1333-1339

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Single-dose daclizumab induction therapy in patients with liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Current practices: immunosuppression induction, maintenance, and rejection regimens in contemporary post-heart transplant patient treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

The effect of Daclizumab in a high-risk renal transplant population

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Data sources and structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Mortality rates after heart transplantation: how to compare center-specific outcome data?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Association of center volume with outcome after liver and kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.12.135

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2004.12.135

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15848713%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42654373&oldid=1578235450"